Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1992 2
1993 11
1994 17
1995 32
1996 32
1997 53
1998 45
1999 39
2000 56
2001 50
2002 46
2003 71
2004 58
2005 76
2006 56
2007 55
2008 56
2009 74
2010 81
2011 76
2012 82
2013 103
2014 88
2015 113
2016 101
2017 130
2018 132
2019 181
2020 172
2021 230
2022 204
2023 238
2024 83

Text availability

Article attribute

Article type

Publication date

Search Results

2,525 results

Results by year

Filters applied: . Clear all
Page 1
KMT2A: Umbrella Gene for Multiple Diseases.
Castiglioni S, Di Fede E, Bernardelli C, Lettieri A, Parodi C, Grazioli P, Colombo EA, Ancona S, Milani D, Ottaviano E, Borghi E, Massa V, Ghelma F, Vignoli A, Lesma E, Gervasini C. Castiglioni S, et al. Genes (Basel). 2022 Mar 15;13(3):514. doi: 10.3390/genes13030514. Genes (Basel). 2022. PMID: 35328068 Free PMC article. Review.
KMT2A has a crucial role in gene expression, thus it is associated to pathological conditions when found mutated. ...On the other hand, KMT2A somatic mutations have been reported in several tumors, mainly blood malignancies. ...
KMT2A has a crucial role in gene expression, thus it is associated to pathological conditions when found mutated. ...On the other han …
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. Issa GC, et al. Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15. Nature. 2023. PMID: 36922593 Free PMC article. Clinical Trial.
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function(1-3). The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by eithe …
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function(1-3). The inter …
The KMT2A recombinome of acute leukemias in 2023.
Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, Sutton R, Venn NC, Cazzaniga G, Corral Abascal L, Tsaur G, Fechina L, Emerenciano M, Pombo-de-Oliveira MS, Lund-Aho T, Lundán T, Montonen M, Juvonen V, Zuna J, Trka J, Ballerini P, Lapillonne H, Van der Velden VHJ, Sonneveld E, Delabesse E, de Matos RRC, Silva MLM, Bomken S, Katsibardi K, Keernik M, Grardel N, Mason J, Price R, Kim J, Eckert C, Lo Nigro L, Bueno C, Menendez P, Zur Stadt U, Gameiro P, Sedék L, Szczepański T, Bidet A, Marcu V, Shichrur K, Izraeli S, Madsen HO, Schäfer BW, Kubetzko S, Kim R, Clappier E, Trautmann H, Brüggemann M, Archer P, Hancock J, Alten J, Möricke A, Stanulla M, Lentes J, Bergmann AK, Strehl S, Köhrer S, Nebral K, Dworzak MN, Haas OA, Arfeuille C, Caye-Eude A, Cavé H, Marschalek R. Meyer C, et al. Leukemia. 2023 May;37(5):988-1005. doi: 10.1038/s41375-023-01877-1. Epub 2023 Apr 5. Leukemia. 2023. PMID: 37019990 Free PMC article.
Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2A gene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determ …
Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints with …
Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia.
Górecki M, Kozioł I, Kopystecka A, Budzyńska J, Zawitkowska J, Lejman M. Górecki M, et al. Biomedicines. 2023 Mar 8;11(3):821. doi: 10.3390/biomedicines11030821. Biomedicines. 2023. PMID: 36979800 Free PMC article. Review.
The presence of distinct KMT2A rearrangements is an independent dismal prognostic factor, while very few KMT2A rearrangements display either a good or intermediate outcome. KMT2A-rearranged (KMT2A-r) ALL affects more than 70% of new ALL diagnoses in in …
The presence of distinct KMT2A rearrangements is an independent dismal prognostic factor, while very few KMT2A rearrangements …
Unraveling KMT2A-rearranged ALL.
Shimony S, Luskin MR. Shimony S, et al. Blood. 2023 Nov 23;142(21):1764-1766. doi: 10.1182/blood.2023021942. Blood. 2023. PMID: 37995105 No abstract available.
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes.
Sparbier CE, Gillespie A, Gomez J, Kumari N, Motazedian A, Chan KL, Bell CC, Gilan O, Chan YC, Popp S, Gough DJ, Eckersley-Maslin MA, Dawson SJ, Lehner PJ, Sutherland KD, Ernst P, McGeehan GM, Lam EYN, Burr ML, Dawson MA. Sparbier CE, et al. Nat Cell Biol. 2023 Feb;25(2):258-272. doi: 10.1038/s41556-022-01056-x. Epub 2023 Jan 12. Nat Cell Biol. 2023. PMID: 36635503 Free PMC article.
While Menin and KMT2A/B contribute to H3K4me3 at active genes, a separate Menin-independent function of KMT2A/B maintains H3K4me3 and opposes polycomb-mediated repression at bivalent genes. Release of KMT2A from active genes following Menin targeting alters t …
While Menin and KMT2A/B contribute to H3K4me3 at active genes, a separate Menin-independent function of KMT2A/B maintains H3K4 …
KMT2A-rearranged leukemia: the shapeshifter.
Iacobucci I, Mullighan CG. Iacobucci I, et al. Blood. 2022 Oct 27;140(17):1833-1835. doi: 10.1182/blood.2022017645. Blood. 2022. PMID: 36301633 Free article. No abstract available.
Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia.
Chen C, Yu W, Alikarami F, Qiu Q, Chen CH, Flournoy J, Gao P, Uzun Y, Fang L, Davenport JW, Hu Y, Zhu Q, Wang K, Libbrecht C, Felmeister A, Rozich I, Ding YY, Hunger SP, Felix CA, Wu H, Brown PA, Guest EM, Barrett DM, Bernt KM, Tan K. Chen C, et al. Blood. 2022 Apr 7;139(14):2198-2211. doi: 10.1182/blood.2021013442. Blood. 2022. PMID: 34864916 Free PMC article.
KMT2A-rearranged (KMT2A-r) infant acute lymphoblastic leukemia (ALL) is a devastating malignancy with a dismal outcome, and younger age at diagnosis is associated with increased risk of relapse. To discover age-specific differences and critical drivers that mediate …
KMT2A-rearranged (KMT2A-r) infant acute lymphoblastic leukemia (ALL) is a devastating malignancy with a dismal outcome, and yo …
KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.
Assaf N, Liévin R, Merabet F, Raggueneau V, Osman J, Kim R, Garnache F, D'Angiò M, Larghero P, Meyer C, Marschalek R, Rousselot P, Terré C. Assaf N, et al. Mol Biol Rep. 2021 Oct;48(10):7021-7027. doi: 10.1007/s11033-021-06621-5. Epub 2021 Aug 12. Mol Biol Rep. 2021. PMID: 34383244 Review.
BACKGROUND: The detection of KMT2A gene rearrangements have an important impact on the prognosis and management of acute leukemias. These alterations most commonly involve reciprocal translocations at specific breakpoint regions within KMT2A. To date, more than 100 …
BACKGROUND: The detection of KMT2A gene rearrangements have an important impact on the prognosis and management of acute leukemias. T …
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Pollard JA, et al. J Clin Oncol. 2021 Oct 1;39(28):3149-3160. doi: 10.1200/JCO.20.03048. Epub 2021 May 28. J Clin Oncol. 2021. PMID: 34048275 Free PMC article. Clinical Trial.
PURPOSE: We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on survival in pediatric patients with KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) enrolled in the Children's Oncology Group trial AAML0531 (NCT01407757). METHODS: …
PURPOSE: We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on survival in pediatric patients with KMT2A …
2,525 results